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Abstract
Background: Little is known about the comparative effects of different glucocorticoids on the adrenal and growth
hormone (GH) axes in children with congenital adrenal hyperplasia (CAH). We sought to compare the effects of
hydrocortisone (HC), prednisone (PDN), and dexamethasone (DEX) in children with classic CAH and to investigate a
potential role of pharmacogenetics.
Methods: Subjects were randomly assigned to three sequential 6-week courses of HC, PDN, and DEX, each
followed by evaluation of adrenal hormones, IGF-1, GH, and body mass index (BMI). Single nucleotide polymorphism
(SNP) analysis of genes in the glucocorticoid pathway was also performed.
Results: Nine prepubertal subjects aged 8.1 ± 2.3 years completed the study. Mean ACTH, androstenedione, and
17-hydroxyprogesterone (17-OHP) values were lower following the DEX arm of the study than after subjects received
HC (p ≤ 0.016) or PDN (p ≤ 0.002). 17-OHP was also lower after HC than PDN (p < 0.001). There was no difference
in IGF-1, GH, or change in BMI. SNP analysis revealed significant associations between hormone concentrations,
pharmacokinetic parameters, and variants in several glucocorticoid pathway genes (ABCB1, NR3C1, IP013, GLCCI1).
Conclusions: DEX resulted in marked adrenal suppression suggesting that its potency relative to hydrocortisone
and prednisone was underestimated. SNPs conferred significant differences in responses between subjects.
Although preliminary, these pilot data suggest that incorporating pharmacogenetics has the potential to
eventually lead to targeted therapy in children with CAH.
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Background
Classic congenital adrenal hyperplasia (CAH) due to
21-hydroxylase deficiency results from an enzymatic block
in the biosynthesis of cortisol and aldosterone. Treatment
of classic CAH in children involves a challenging balance
between androgen excess leading to bone age advancement
due to under treatment with glucocorticoids and cortisol
excess leading to impaired linear growth from overtreat-
ment [1]. Hydrocortisone (HC) is the preferred gluco-
corticoid in children with CAH due to potential concerns
of linear growth suppression associated with longer-acting
and more potent glucocorticoid formulations [1, 2]. How-
ever, while experience is limited, dexamethasone (DEX)
and single or multiple doses of prednisone (PDN) have
been used successfully in children with CAH [3, 4].
Little is known about the comparative effects of HC,
PDN, and DEX on the hypothalamic-pituitary-adrenal
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(HPA) and growth hormone axes in CAH. The aim of
this pilot study was to compare hormonal and pharma-
cokinetic profiles after short-term treatment with HC,
PDN, and DEX in children with CAH. Additional stud-
ies were performed to determine if variants in genes in
the glucocorticoid pathway were associated with individ-
ual differences in responses to treatment.
Methods
Subjects and study design
Prepubertal children between the ages of 4 and 12 years
with classic CAH followed at Riley Hospital for Children
were eligible for enrollment. Exclusion criteria included
medical problems that affect growth, absorption, or
clearance of glucocorticoids and medications known to
affect the absorption or clearance of glucocorticoids.
The study was approved by the Institutional Review
Board at Indiana University, and written informed con-
sent from parents and assent from subjects, when appro-
priate, was obtained. All visits were conducted at the
Indiana University General Clinical Research Center
(GCRC). At the time of enrollment, a physical exam was
performed, including height, weight, vital signs, and
Tanner staging. A bone age radiograph was obtained if
one had not been done within the past 6 months. Baseline
blood tests at enrollment included 17-hydroxyprogesterone
(17-OHP), androstenedione, and electrolytes.
Subjects were assigned to three sequential 6-week treat-
ment courses arranged in random order during which
they received the following medications: hydrocortisone
(5 mg tablets; Pfizer, New York, NY) 15 mg/m2/day
divided three times a day administered at 08:00, 15:00,
and 21:00; prednisone (1 mg tablets; Roxane Laboratories
Inc., Columbus, OH) 3 mg/m2/day divided twice a day
administered at 08:00 and 21:00; and dexamethasone
(0.5 mg/5 mL elixir; Morton Grove Pharmaceuticals Inc.,
Morton Grove, IL) 0.3 mg/m2/day administered daily at
21:00. All medications were taken orally. The bioequiva-
lence and potency conversion of HC to PDN to DEX was
estimated to be 1 to 5 to 50, based on clinical practice
guidelines from the Endocrine Society regarding gluco-
corticoid dosing in CAH [1]. A pill cutter and oral syringe
were given to each subject. Subjects remained on their
usual dose of mineralocorticoid replacement throughout
the study. Subjects were instructed to administer stress
dose steroids by tripling the oral dose of glucocorticoid in
times of illness or fever. If stress dosing was administered
within a week of a scheduled GCRC admission, it was
postponed until the subject had not received stress dose
steroids for at least 7 days.
At the end of each 6-week period, subjects were
admitted to the GCRC for 25 h. A physical exam was
performed, including height, weight, vital signs, and
Tanner staging. A peripheral IV was placed from which
all blood samples were obtained. At 08:00, sodium,
potassium, IGF-1, 17-OHP, and androstenedione were
measured. For those taking HC, cortisol was measured
before the 08:00 dose and then at 20, 40, 60, 80, 120,
and 240 min in order to evaluate cortisol metabolism
and clearance. While on PDN, cortisol was measured as
a surrogate for PDN metabolism and clearance. When
patients were on DEX, a dexamethasone level was
drawn at 20:00 before the 21:00 DEX dose was adminis-
tered. Measurements of 17-OHP were obtained every
2 h (13 total per each overnight stay); growth hormone
every hour from 20:00 to 08:00 (13 total per each over-
night stay); adrenocorticotropic hormone (ACTH) at
14:00 and then every 2 h from 00:00 to 06:00 (5 total
per each overnight stay); and androstenedione at 20:00
(2 total per each overnight stay). At the first GCRC ad-
mission, 5 mL of blood was drawn and frozen in the
GCRC Pharmacogenetic Core Lab to be used for DNA
extraction.
All subjects were contacted by telephone two weeks
after starting a new glucocorticoid regimen to review
administration and compliance. Pill counts and deter-
mination of elixir volumes were performed at GCRC
admissions to assess compliance. At the end of the 18-week
study, subjects returned to their pre-study glucocorticoid
regimen.
Laboratory assays
All blood samples were analyzed at the GCRC, except
for genomics and dexamethasone samples which were
analyzed at Esoterix (Calabasas Hills, CA) by high per-
formance liquid chromatography (HPLC) tandem mass
spectrometry. Standard clinical laboratory methods
were used to measure serum electrolytes. 17-OHP was
measured by radioimmunoassay (RIA) (MP Biomedi-
cals, Orangeburg, NY). The following hormones were
measured by enzyme-linked immunosorbent assay
(ELISA): cortisol, androstenedione, ACTH, IGF-1
(ALPCO Diagnostics, Salem, NH) and growth hor-
mone (Alpha Diagnostic, Inc., San Antonio, TX).
DNA was extracted with QIAGEN QIAamp® DNA
Blood Mini and Maxi kits (QIAGEN, Valencia, CA) and
genotyped for single nucleotide polymorphisms (SNPs) in
genes in the glucocorticoid pathway as previously de-
scribed [5]. SNPs analyzed included those in the following
genes: importin 13 or IPO13 (rs6671164, rs4448553,
rs1990150, rs2240447, rs2486014, rs2301993, rs7412307,
rs2428953), nuclear receptor subfamily 3, group C, mem-
ber 1 or NR3C1 (rs41423247), glucocorticoid-induced
transcript 1 or GLCCI1 (rs37973), ATP-binding cassette,
subfamily B, member 1 or ABCB1 (rs1045642, rs2032582,
rs1128503), cytochrome P450, subfamily IIIA, polypeptide
7 or CYP3A7 (rs2257401, rs2687133), stress-induced
phosphoprotein 1 or STIP1 (rs2236647), low density
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lipoprotein, oxidized, receptor 1 or OLR1 (rs3736233),
adenylate cyclase 2 or ADCY2 (rs2230739), corticotropin-
releasing hormone receptor 1 or CRHR1 (rs242941,
rs1876828), and Fc fragment of IgE, low affinity II, recep-
tor for or FCER2 (rs28364072).
Statistical analysis
Statistical analyses were performed to determine if there
was an association between the three glucocorticoids
and biochemical and anthropometric outcomes. These
outcomes were measured over time, and thus each par-
ticipant had multiple measures for each outcome. Gen-
eralized linear models were used to analyze the data in
order to account for repeated measures and to ensure
that the proper covariance structure was used. Pairwise
comparisons were also performed using a Bonferroni
correction. Overall analyses were considered significant
at p ≤ 0.05 and pairwise comparisons among the three
drugs were considered significant at p ≤ 0.017. All ana-
lytic assumptions were verified and log transformed
when the data did not follow the normal distribution.
For 17-OHP, additional analyses were performed to
determine the proportion of time spent within the pre-
determined target range of 100–1000 ng/dL. Each time
point was connected with a straight line to its next
neighbor and integration methods were performed to
derive the total area and specified target areas. ANOVA
models were used to determine if there was a significant
difference in the proportion of time within the target
range between the study drugs.
BMI z-scores were generated using the Center for
Disease Control’s growth chart training resource.
ANCOVA models were used to determine if there was
a significant difference in BMI z-scores following treat-
ment with the three different study drugs. As the gluco-
corticoids were administered at different combinations,
this analysis was adjusted for the previous drug that the
subject was on.
All analytic assumptions were verified. All analyses were
performed using SAS v9.3 (SAS Institute, Cary, NC).
The pharmacokinetic measurements were based on
three summaries: average, area under the concentration
curve (AUC), and decreasing rate or slope. The average
was calculated based on the average measurement
among all sampling time points. The AUC was calcu-
lated based on the trapezoid rule, and the decreasing
rate was calculated based on the measurements from the
last three sampling time points.
The associations between relevant phenotypes and
SNPs were assessed through three different genetic
models: dominant, recessive, and additive. The dominant
model compares the genotype homozygous dominant
(XX) with the genotypes containing one or both
recessive, or variant alleles (Xx or xx). The recessive
model compares the genotype homozygous recessive
(xx) versus genotypes with one or both dominant alleles
(XX or Xx). An additive model examines whether each
copy of an allele contributes to an additional risk, so XX
would be the highest, Xx would have less risk, and xx
would have no risk [6]. Linear regression was applied to
analyze these genetic associations. T-tests were used to
determine directionality. As this was an exploratory
analysis, any association with a p-value ≤ 0.05 was
considered statistically significant. The Bonferroni
justification was not applied in the genetic data ana-
lysis. The genetic data analyses were conducted in PLINK
(http://pngu.mgh.harvard.edu/purcell/plink/).
Results
Subjects
Nine subjects with classic CAH (8 with salt-wasting and
1 with simple virilizing) aged 8.1 ± 2.3 years (range: 4.8–
11.6 years) completed the study. Four additional subjects
were enrolled but withdrew due to difficulty maintaining
peripheral IV access. One additional subject was ex-
cluded when his screening visit revealed he was pubertal.
No other subjects met exclusion criteria. Patient charac-
teristics including baseline hormonal values at study
entry are summarized in Table 1. Electrolytes and vital
signs were normal in all subjects.
Hormonal studies and BMI z-scores
Mean ACTH, androstenedione, and 17-OHP values were
all significantly lower following treatment with DEX
when compared to HC (p = 0.016, p = 0.016, p < 0.001)
and PDN (p < 0.001, p = 0.002, p < 0.001). Interestingly,
17-OHP levels were significantly lower following treat-
ment with HC than on PDN (p < 0.001). No other differ-
ences in adrenal hormones between treatment groups
were seen. IGF-1 levels did not differ among the three
treatment groups (p = 0.980), nor did GH levels (p =
0.127), or change in BMI z-scores (p = 0.648). Mean
IGF-1 SDS (adjusted for age, gender, and Tanner stage)
also did not differ for each glucocorticoid (p = 0.957):
HC (1.57), PDN (1.61), and DEX (1.78). Representative
GH profiles showing preserved GH pulsatility from three
of the subjects are shown in Fig. 1. None of the subjects
exhibited clinical signs of glucocorticoid excess during
the study. The significant differences in hormone levels
between treatment pairs are summarized in Table 2.
Mean 17-OHP values were lowest on DEX and highest
on PDN at each measured time point (Fig. 2). The ma-
jority of 17-OHP values during treatment with each
glucocorticoid were outside of the target range (75 % for
DEX, 70 % for HC, and 80 % for PDN) and did not differ
between groups (p = 0.714).
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Dexamethasone levels
Eight subjects had trough DEX levels of < 30 ng/dL. Only
one subject had a detectable DEX level of 56 ng/dL, which
corresponded to low 17-OHP and androstenedione
concentrations. However, 17-OHP measurements in
three subjects with undetectable DEX levels were nearly
all < 100 ng/dL and androstenedione levels were also
low.
Pharmacokinetics and pharmacogenetics
As illustrated in Fig. 3, there was variability in gluco-
corticoid metabolism and pharmacokinetics between
subjects. Due to the small sample size, data analysis is
reported using dominant genetic models, which examine
the associations between carrying the dominant allele
for each SNP and downstream pharmacokinetic effects.
Based on the dominant model analyses, gene variants
were correlated with hormone concentrations. First, for
ABCB1 (rs2032582 and rs1045642), subjects carrying at
least one copy of the variant (GA or AA) had signifi-
cantly lower concentrations of 17-OHP on the DEX arm
as compared to subjects with the homozygous wild-type
(GG) genotype (p = 0.025 for both). Showing a similar
trend for ABCB1 (rs1128503) when on DEX, subjects
carrying at least one variant allele (CA or AA) had sig-
nificantly lower concentrations of 17-OHP compared to
homozygous wild-type (CC) subjects (p = 0.025). For
NR3C1 (rs41423247), subjects with at least one copy of
the variant allele (GC or CC) had significantly higher
concentrations of androstenedione when on PDN as
compared to homozygous wild-type (GG) subjects (p =
0.004). There were no significant genetic associations
identified when subjects were on HC. These results are
shown in Table 3 and Fig. 4.
To investigate total drug exposure over time, area
under the concentration curve (AUC) analysis was per-
formed, with significant associations noted only during
the PDN arm of the study (Table 4). For importin-13
(IPO13, rs6671164 and rs7412307), subjects homozygous
for the variant allele had the least exposure to glucocortic-
oid followed by those who were heterozygous for the vari-
ant followed by those homozygous for the wild-type (p =
0.015 for all). Inversely, for IPO13 variants rs4448553,
rs1990150, rs2240447, rs2301993, and rs2428953, subjects
who were homozygous for the variant allele had the most
exposure to glucocorticoid followed by those who were
homozygous for the wild type followed by subjects who
were heterozygous for the variant (p ≤ 0.023 for all). Lastly,
subjects who were heterozygous for the variant allele for
Table 1 Baseline characteristics at enrollment of subjects who
completed all 3 arms of the study
Number of subjects 9 (5 female)
Glucocorticoid regimen prior to entering
the study
Hydrocortisone (7),
prednisone (2)
Dose of hydrocortisone (mg/m2/day)
equivalent
15.6 ± 4.0
Age (years) 8.1 ± 2.3
Bone age (years) 8.6 ± 2.9
Height (cm); z-score 127.6 ± 17.9; 0.0 ± 1.2
Weight (kg); z-score 39.1 ± 24.0; 1.0 ± 1.4
BMI (kg/m2); z-score 22.0 ± 8.1; 1.2 ± 1.1
17-hydroxyprogesterone (ng/dL) 991.1 ± 978.5
89.4 (0.4–2500.0)
Androstenedione (ng/dL) 35.2 ± 22.5
22.3 (2.0–392.0)
Values are mean ± standard deviation, with 17-hydroxyprogesterone and
androstenedione also including median (minimum – maximum) due to
data skewness
Fig. 1 Representative GH profiles in three subjects. There is normal
variability and pulsatility of GH secretion for each glucocorticoid
(solid line for PDN, solid-dash line for HC, and dashed line for DEX)
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the glucocorticoid induced transcript 1 (GLCCI1, rs37973)
had the least exposure to glucocorticoid followed by those
homozygous for the wild-type followed by subjects who
were homozygous for the variant allele (p = 0.037 for all).
There were no significant correlations identified for these
gene variants when subjects were on HC or DEX.
Slope analysis was performed to determine cortisol
clearance (Table 4). Using the dominance model, sub-
jects homozygous for ABCB1 variants (rs1045642,
rs2032582, and rs1128503) had faster clearance of
cortisol while on HC as compared to homozygous
wild-type subjects (p = 0.026, p = 0.026, and p = 0.026,
respectively). There were no significant correlations
between gene variants and cortisol clearance for sub-
jects on PDN.
Discussion
This pilot study compared the hormonal effects and
pharmacokinetic profiles of HC, PDN, and DEX in nine
prepubertal children with classic CAH. We used a po-
tency conversion between HC to PDN to DEX of 1 to 5
to 50. However, our data demonstrate that DEX was
more potent than both HC and PDN as children on the
DEX arm had significantly lower adrenal hormone levels
compared to those on either HC or PDN. Although
glucocorticoid equivalencies are debatable, our findings
are in line with other studies suggesting that DEX is at
least 70 times [3] and up to 80 to 100 times or more
[7–9] potent than HC in regards to suppressing adrenal
androgen production. Unlike for DEX, we did not find
any difference in ACTH or androstenedione concentra-
tions during treatment with HC and PDN. In contrast,
17-OHP values were significantly higher when children
were receiving PDN than when they were treated with
HC. This suggests that PDN may be ≤ 5 fold more po-
tent than HC and conflicts with other reports suggest-
ing that PDN is 10 to 15 times more potent than HC
Table 2 Summary of differences of log transformed data between treatment pairs
Drug
pair
ACTH Androstenedione 17-OHP
Difference (95 % CI) p-value Difference (95 % CI) p-value Difference (95 % CI) p-value
DEX-HC −0.55 (−0.99, −0.12) 0.016** −0.64 (−1.15, −0.14) 0.016** −1.59 (−1.94, −1.23) < 0.001**
DEX-PDN −0.90 (−1.33, −0.47) < 0.001** −0.90 (−1.40, −0.40) 0.002** −2.44 (−2.80, −2.09) < 0.001**
HC- PDN −0.35 (−0.78, 0.09) 0.110 −0.26 (−0.76, 0.25) 0.293 −0.86 (−1.21, −0.50) < 0.001**
Values are expressed as the difference between drug groups (first drug minus the second drug) with 95 % confidence interval (CI)
** Significant p-value is ≤ 0.017
Fig. 2 Mean 17-hydroxyprogesterone (17-OHP) concentration by
time points. 17-OHP was measured every 2 h during each inpatient
stay from 08:00 to 08:00 the next day. 17-OHP was lowest on DEX
and highest on PDN at each time point (p < 0.001). Bars represent
the 95 % confidence interval for the standard error
Fig. 3 Variable cortisol pharmacokinetics were noted in subjects
taking hydrocortisone (HC) and prednisone (PDN). For example, the
subject in (a) metabolized and cleared glucocorticoids faster than
the subject in (b)
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[9, 10]. It is important to note that these findings may
not reflect what is seen with prednisolone, which is the
active metabolite of PDN.
Laboratory monitoring during glucocorticoid therapy
in children with CAH is difficult since hormone concen-
trations can vary widely depending on the time of day
and most recent glucocorticoid dose [11]. By measuring
frequent hormone levels during each inpatient stay, we
were able to characterize the degree of hormone vari-
ability. In particular, there were wide fluctuations in 17-
OHP levels within individual subjects demonstrating
that a single 17-OHP measurement is problematic in
terms of reflecting the degree of biochemical control.
This marked variability in 17-OHP has been attributed
to circadian patterns [12, 13] and exaggerated responses
to stress [14, 15]. Androstenedione also has a circadian
rhythm but the magnitude of variability is less than that
seen with 17-OHP [16] and levels often correlate better
with overall CAH control [17]. Although not routinely
used in the management of CAH, ACTH levels have
been shown to be a useful adjunct [18], and as seen in
our study, often correlate with other hormone markers
of biochemical control.
Nightly dosing of DEX can lead to overtreatment with
greater suppression of early morning adrenal steroid
concentrations [19, 20]. All but one of our subjects had
an undetectable trough DEX level, but many of our sub-
jects on DEX had low 17-OHP and androstenedione
levels. This implies that trough DEX levels do not accur-
ately reflect the biological effect at a tissue or cellular
level. Despite disparities in adrenal steroids, there was
no difference in GH, IGF-1, or BMI during treatment
with the three glucocorticoids. However, given the short
duration of our study, any presumption regarding the
implication of this observation on long-term growth
would be premature.
Very few studies, also with small sample sizes, have
compared different glucocorticoids in either children or
adults with CAH [7, 20–22], and ours is the only one to
compare three different preparations in a prepubertal
cohort. While overall results have been conflicting, other
investigators have also noted a greater degree of sup-
pression than expected with DEX [7], as was the case in
our study. In our study, significant correlations were
found between ABCB1, NR3C1, IPO13 and GLCCI1 ge-
notypes and hormone concentrations and/or clearance.
While such findings could be spurious, it is intuitive that
differences in glucocorticoid-related genes could impact
individual physiologic responses. The ABCB1 gene en-
codes for P-glycoprotein, which is a transmembrane
transporter that acts as a cellular drug efflux pump for
various substances, including glucocorticoids [23]. Clin-
ical response to glucocorticoids has been shown to be
influenced by individual SNPs as well as haplotypes in
ABCB1 [24, 25]. For example, polymorphisms in ABCB1
have been associated with steroid resistance in children
with nephrotic syndrome [26, 27] and steroid response
Table 3 Average association analysis using a dominant model of genetic variants and their effect on hormone levels during
glucocorticoid treatments
Hormone Drug Gene CHR SNP Basepair Minor allele N P value
Androstenedione Prednisone NR3C1 5 rs41423247 142778575 C 8 0.004
17-OHP Dexamethasone ABCB1 7 rs1045642 87138645 A 9 0.025
17-OHP Dexamethasone ABCB1 7 rs2032582 87160618 A 9 0.025
17-OHP Dexamethasone ABCB1 7 rs1128503 87179601 A 9 0.025
Abbreviations: CHR chromosome, SNP single nucleotide polymorphism, N number, 17-OHP 17-hydroxyprogesterone, NR3C1 nuclear receptor subfamily 3 group C
member 1, ABCB1 ATP-binding cassette sub-family B
Fig. 4 In a, when comparing the ABCB1 *1 dominant haplotype
with the ABCB1 recessive haplotypes *1/*2 and *2, the subjects
homozygous for the *1 haplotype had less suppression of 17-OHP
on DEX compared to the others. In b, those expressing the dominant
genotype had greater suppression of androstenedione on PDN
than the recessive genotype
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in those with inflammatory bowel disease [28, 29]. In
our study, subjects with specific ABCB1 genetic variants
were found to metabolize and clear cortisol faster when
on HC. Polymorphisms in ABCB1 and other relevant
genes might explain why some patients with CAH re-
quire unexpectedly low or high doses of glucocorticoids
to achieve optimal biochemical control, and preemptive
genetic testing may facilitate selection of a more appro-
priate starting dose for individual patients. Further-
more, experimental regimens and novel medical
therapies currently under investigation may eventually
make a one glucocorticoid approach obsolete in the
treatment of CAH.
The NR3C1 gene encodes for the glucocorticoid recep-
tor (GR). Other research has shown that individuals
with the BclI (rs41423247) polymorphism have in-
creased sensitivity and responsiveness to glucocorti-
coids [30, 31]. This SNP has also been associated
with increased BMI, hypertension, and cardiovascular
disease in the general population [32]. Adults with
CAH who possess the BclI polymorphism have also
been found to have a higher BMI, waist circumfer-
ence, and systolic blood pressure [33] but this has
not been found in children [34]. We did not evaluate
for correlations with BMI in our subjects with this
SNP given the small size of our population. However,
we did find significant associations between the
rs41423247 variant and androstenedione concentrations
when subjects were on PDN.
Subjects in our study with genetic variants in IPO13
and GLCCI1 had variable exposure to glucocorticoids
when on PDN. Both IPO13 and GLCCI1 genotypes are
associated with glucocorticoid exposure in children on
PDN [35, 36]. IPO13 regulates the nuclear translocation of
the GR. Polymorphisms of IPO13 have been associated with
airway hyper-responsiveness and reactivity in children
with asthma, suggesting that IPO13 variation might
improve endogenous glucocorticoid bioavailability in
the cell nucleus [35]. The function of GLCCI1 is not
well understood. SNPs in GLCCI1 in patients with
asthma have been associated with a decreased response
to inhaled glucocorticoids [36]. However, differences
in gene variants of GLCCI1 have not been shown to
be significant in other diseases, such as steroid resistant
nephrotic syndrome [37].
Limitations of our pilot study include the small sample
size, lack of a washout period, previous treatment with
different glucocorticoids, and short exposure to each
glucocorticoid. Although significant pharmacogenetic
correlations were detected, it is premature to draw firm
conclusions about the possible functional role of these
genetic variants [38]. Another limitation is that hormone
levels were measured using RIA and ELISA instead of
more precise techniques, such as liquid chromatography
and tandem mass spectrometry; however, this is similar
to the clinical setting. Finally, we acknowledge that the
potency conversion used in our study is open to debate.
Determining equivalent glucocorticoid dosing is com-
plex, varies between individuals and can be based on
anti-inflammatory effect, growth-retarding effect, and/or
androgen-suppressive effect. For example, while DEX
may be up to 80 times more potent than cortisol for
growth-retarding effect, it appears to be only 30 times
more potent than cortisol in regards to anti-inflammatory
effect [39]. While extremely preliminary, our findings are
intriguing and warrant replication in a larger population
to see if there is a true differential versus a dose or
equivalency-related effect.
Table 4 Area under the curve and slope analysis of cortisol for genetic variants
Drug Gene CHR SNP Basepair Minor allele N P value
Area under the curve analysis:
Prednisone IPO13 1 rs6671164 44403489 G 8 0.015
Prednisone IPO13 1 rs4448553 44411589 A 9 0.007
Prednisone IPO13 1 rs1990150 44414127 G 9 0.023
Prednisone IPO13 1 rs2240447 44415415 C 9 0.007
Prednisone IPO13 1 rs2301993 44426025 C 9 0.007
Prednisone IPO13 1 rs7412307 44433864 G 8 0.015
Prednisone IPO13 1 rs2428953 44443459 A 9 0.023
Prednisone GLCCI1 7 rs37973 8007876 G 9 0.038
Slope analysis:
Hydrocortisone ABCB1 7 rs1045642 87138645 A 9 0.026
Hydrocortisone ABCBI 7 rs2032582 87160618 A 9 0.026
Hydrocortisone ABCB1 7 rs1128503 87179601 A 9 0.026
Abbreviations: CHR chromosome, SNP single nucleotide polymorphism, IPO13 importin-13, GLCCI1 glucocorticoid-induced transcript 1, ABCB1 ATP-binding cassette
sub-family B member 1
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Conclusions
It would be unrealistic to expect there to be one best
glucocorticoid regimen for all children with classic
CAH. In our subjects, DEX resulted in over dosing while
PDN often lead to under dosing. During treatment with
each glucocorticoid, there was a great deal of individual
variability in hormone concentrations. The majority of
17-OHP values were outside of the target range, suggest-
ing that 17-OHP measurements to guide glucocorticoid
dosing are problematic at best. Given inherent differ-
ences in individual physiology, pharmacogenetics may
help to predict steroid sensitivity and response in
patients with CAH. Ultimately, such information could
lead to more targeted dosing for individual patients
resulting in improved clinical care.
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